Juan Camilo Arjona Ferreira

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 404 citations

Life Sciences, Infectious Diseases, Microbiology +10

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

Juliana C.N. Chan, Russell Scott, Juan Camilo Arjona Ferreira et al. · Diabetes Obesity and Metabolism · 2008 · 238 citations

Medicine, Pharmacology, Pharmacotherapy +16

Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy

Ayman Al‐Hendy, Andrea S. Lukes, Alfred N. Poindexter et al. · New England Journal of Medicine · 2021 · 201 citations · Full text

Medicine, Gynecology, Pharmacotherapy +17

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

Bin Cai, Roger Echols, Glenn Magee et al. · Open Forum Infectious Diseases · 2017 · 197 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

Juan Camilo Arjona Ferreira, Michel Marre, Nir Barzilai et al. · Diabetes Care · 2012 · 159 citations · Full text

Medicine, Nephrology, Pharmacotherapy +14